AbCellera Biologics Inc. Increase (Decrease) in Royalties Payable
AbCellera Biologics Inc. (ABCL) reported Increase (Decrease) in Royalties Payable of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRoyaltiesPayable · last filed 2024-11-04
- AbCellera Biologics Inc. increase (decrease) in royalties payable for the quarter ending 2024-09-30 was $0.00.
- AbCellera Biologics Inc. increase (decrease) in royalties payable for the quarter ending 2024-06-30 was $0.00.
- AbCellera Biologics Inc. increase (decrease) in royalties payable for the quarter ending 2024-03-31 was $0.00.
- AbCellera Biologics Inc. increase (decrease) in royalties payable for the quarter ending 2023-09-30 was $0.00.
- AbCellera Biologics Inc. increase (decrease) in royalties payable for fiscal 2022 was -$3.16M.
- AbCellera Biologics Inc. increase (decrease) in royalties payable for fiscal 2021 was -$4.64M, a 117.08% decline from fiscal 2020.
- AbCellera Biologics Inc. increase (decrease) in royalties payable for fiscal 2020 was $27.14M.
| Period end | Increase (Decrease) in Royalties Payable 3 month | Increase (Decrease) in Royalties Payable 6 month | Increase (Decrease) in Royalties Payable 9 month | Increase (Decrease) in Royalties Payable 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | -$16.25M 10-Q · filed 2024-11-04 | -$14.73M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$16.25M 10-Q · filed 2024-08-06 | -$14.73M derived: sum of 3 quarters · filed 2024-08-06 | -$47.46M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$16.25M 10-Q · filed 2024-05-07 | -$14.73M derived: sum of 2 quarters · filed 2024-05-07 | -$47.46M derived: sum of 3 quarters · filed 2024-05-07 | -$42.27M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$31.21M derived: sum of 2 quarters · filed 2023-11-02 | -$26.02M derived: sum of 3 quarters · filed 2023-11-02 | -$3.16M 10-K · filed 2023-02-21 |
| 2022-09-30 | -$32.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$27.54M derived: sum of 2 quarters · filed 2023-11-02 | -$4.68M 10-Q · filed 2023-11-02 | $17.23M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $5.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $28.05M 10-Q · filed 2023-08-03 | $49.96M derived: sum of 3 quarters · filed 2023-08-03 | $27.04M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $22.86M 10-Q · filed 2023-05-04 | $44.77M derived: sum of 2 quarters · filed 2023-05-04 | $21.84M derived: sum of 3 quarters · filed 2023-05-04 | $25.35M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $21.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$1.01M derived: sum of 2 quarters · filed 2023-02-21 | $2.50M derived: sum of 3 quarters · filed 2023-02-21 | -$4.64M 10-K · filed 2023-02-21 |
| 2021-09-30 | -$22.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$19.41M derived: sum of 2 quarters · filed 2022-11-08 | -$26.55M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$3.62M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$7.13M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $27.14M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |